Open Access Open Access  Restricted Access Subscription or Fee Access

Developed Nano-technological Production of Chemotherapeutic Drugs for Targeted Destruction of a Cancerous Tumor

M. Shoikhedbrod


Existing chemotherapeutic drugs do not have the ability to act on a cancerous tumor with a calculated dose and time, corresponding to the cancer cell mitosis, which leads to the unpredictability of the result
of the drug application, and, consequently, to the ineffectiveness of its use in treatment. An indirect effect of a chemotherapeutic drug on cancerous tumor cells leads to damage of normal cells of the patient's body, causing a number of complications, associated with the side effects of chemotherapy.
The paper presents the developed nano-technological production of chemotherapeutic drugs for targeted destruction of a cancerous tumor with precisely calculated dose and time of cytostatic action on tumor cells at the moment of their mitosis (indirect cell division). The drug, obtained by the
developed nano-technological method is a carrier material with uniformly distributed small spherical droplets of cytostatic. The resulting drug is a solid carrier material that melts at the temperature of the human body, which allows it to be implanted in areas of the patient's body that supply blood to the cancerous tumor. Spherical droplets of the cytostatic solution, evenly distributed in the resulting carrier material, when it is melted, purposefully with a calculated dose and time directly act on cancerous
tumor cells at the moment of their mitosis. The calculation of the shock dose and the time of action of the cytostatic solution, exactly attributable to the mitosis of cancer cells, when setting the volume of each drop, their total amount in the carrier material, as well as the melting time of the latter, is quite simple. The calculated dose of cytostatic in the carrier material is achieved by injecting a pre-calculated volume of cytostatic into it in the form of small spherical droplets through a special gap inside the chamber for the molten carrier material by drip bubbling under weightless conditions.

Full Text:



Machak G.N. Modern chemotherapy of the localized form of osteosarcoma. Vestnik RONTS, 2003;14 (1, 2).

Verma R, Foster R, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes T. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Research, 2016; 18:10.

Mir O, Ropert S, Goldwasser F. Cisplatin as a cornerstone of modern chemotherapy. The Lancet Oncology, 2009; 10 (3): 304.

Verrill M. Chemotherapy for early-stage breast cancer: a brief history. British Journal of Cancer, 2009; 101 (S2–S5).

Schuell B, Gruenberger T, Kornek G, Dworan N, Depisch D, Lang F, Schneeweiss, Scheithauer W. Side effects during chemotherapy predict tumor response in advanced colorectal cancer. British Journal of Cancer, 2005; 93:744–748.

Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Kameyama M and others. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepato-gastroenterology, 1997; 44(18):1541–1546.

Arybzhanov D.T., Saburov A.R. Regional chemotherapy in the pre-operation treatment of patients by cancer of stomach, Siberian oncologic periodical, 2009; 1.

Gantsev Sh.Kh., Arybzhanov D.T., Saburov A.R. The results of treating the patients by cancer of stomach with the use of regional chemotherapy and trans-arterial chemoembolization metastases in the liver. New formation, 2017; 16 (1):61.

Balch C, Urist M, McGregor M. Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump: A feasibility study in 50 patients. The American Journal of Surgery, 1983;145 (2):285–290

Shoikhedbrod M.P. Computer modeling and the new technologies in oncology. Lambert Academic publishing, Toronto, 2017.



  • There are currently no refbacks.